Celgene Licenses Rights to EntreMed for Tubulin Inhibitor Program

Celgene announced that it has signed a licensing agreement with EntreMed Corporation whereby EntreMed has been granted rights to the development and commercialization of Celgene's tubulin inhibitor compounds, a class of orally available, anti-proliferative compounds that have demonstrated, in preclinical models, activity against drug-resistant cancer cells, inhibition of inflammatory cytokines and anti-angiogenic activity.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/03-24-2005/0003246530&EDATE=)